What is HbA1c?

Hemoglobin A1c (HbA1c) is a form of hemoglobin that carries glucose attached to it through a nonenzymatic reaction. Red blood cells circulate for approximately 120 days, so the percentage of glycated hemoglobin reflects the average blood glucose concentration over the preceding two to three months. Unlike a fingerstick glucose reading, which captures a single moment, HbA1c offers a weighted average that gives clinicians and patients a reliable picture of long‑term glycemic control.

The test measures the fraction of hemoglobin that has glucose bound to its beta‑chain N‑terminal valine. The higher the blood glucose levels have been over the prior weeks, the more glycation occurs. This makes HbA1c a cornerstone of diabetes management, endorsed by major organizations such as the American Diabetes Association and the World Health Organization.

Why HbA1c Is Central to Diabetes Care

Long‑Term Indicator of Glycemic Control

Daily self‑monitoring of blood glucose (SMBG) or continuous glucose monitoring (CGM) provides valuable real‑time data, but each measurement is just a snapshot. HbA1c fills a different role: it integrates all the highs and lows over many weeks, giving a summary that cannot be influenced by a single high‑carbohydrate meal or an afternoon of exercise. This long‑term view is essential for assessing the effectiveness of treatment plans and for identifying trends that might otherwise go unnoticed.

Predictor of Complications

Decades of research, most notably the Diabetes Control and Complications Trial (DCCT) and the UK Prospective Diabetes Study (UKPDS), have established a clear link between elevated HbA1c and the development of microvascular and macrovascular complications. For every 1% reduction in HbA1c, the risk of diabetic retinopathy, nephropathy, and neuropathy falls by about 40%. Cardiovascular disease risk also declines significantly. These findings explain why achieving and maintaining target HbA1c levels is a primary goal in diabetes management.

Guiding Personalized Treatment

Healthcare providers use HbA1c results to tailor medication regimens, adjust insulin dosing, and refine lifestyle recommendations. For instance, if a patient’s HbA1c rises above the target range despite a good diet and physical activity plan, a provider may add or adjust oral agents (e.g., metformin, SGLT2 inhibitors, GLP‑1 receptor agonists) or insulin therapy. Conversely, a patient whose HbA1c is below target but who is experiencing frequent hypoglycemia might need to reduce medication doses or change the timing of meals and injections.

How HbA1c Is Measured and Reported

The Blood Test

The HbA1c test requires a small venous or capillary blood sample. No fasting is necessary, making it convenient for routine check‑ups. The sample is analyzed in a laboratory using high‑performance liquid chromatography (HPLC), immunoassay, or enzymatic methods. Most laboratories in the United States report results as a percentage; in many other countries, the result is expressed in mmol/mol. Conversion is straightforward: HbA1c (%) = (0.0915 × HbA1c [mmol/mol]) + 2.15 (or use an online calculator).

Standardization and Certification

To ensure consistency and accuracy, the National Glycohemoglobin Standardization Program (NGSP) certifies laboratories. The NGSP sets the reference method (DCCT‑aligned) and allows traceability to the IFCC reference method. When reviewing test results, it is important to confirm that the laboratory is NGSP‑certified, as non‑certified labs may produce less reliable values.

How Often to Test

The ADA recommends testing HbA1c at least twice a year for patients with stable glycemic control and quarterly for those who are not meeting treatment goals or who have recently changed therapy. More frequent testing may be warranted during pregnancy, after a major illness, or when starting a new class of glucose‑lowering medication.

Interpreting HbA1c Levels

Diagnostic Thresholds

  • Normal: HbA1c below 5.7% (39 mmol/mol). This indicates normal glucose metabolism.
  • Prediabetes: HbA1c 5.7%–6.4% (39–46 mmol/mol). This range signals elevated risk for developing type 2 diabetes. Lifestyle intervention can often prevent or delay progression.
  • Diabetes: HbA1c 6.5% (48 mmol/mol) or higher. A confirmatory test on a separate day is needed in asymptomatic patients.

Target Ranges for People with Diabetes

For most nonpregnant adults with diabetes, a reasonable HbA1c target is <7.0% (53 mmol/mol). However, goals are individualized based on age, life expectancy, comorbid conditions, hypoglycemia risk, and patient preference. More stringent targets (e.g., <6.5%) may be appropriate for younger patients with newly diagnosed type 1 diabetes who have no cardiovascular disease and a low risk of severe hypoglycemia. Conversely, less stringent targets (e.g., <8.0%) are often suitable for older adults with multiple comorbidities or a history of recurrent hypoglycemia.

Factors That Can Influence HbA1c Results

Biological and Clinical Factors

Anemia and red blood cell turnover: Conditions that shorten red blood cell survival (e.g., hemolytic anemia, recent blood loss, treatment with erythropoiesis‑stimulating agents) can falsely lower HbA1c because the cells spend less time circulating and become less glycated. In contrast, conditions that prolong red cell lifespan (e.g., iron deficiency anemia) may falsely elevate HbA1c. Patients with renal failure or chronic kidney disease may have altered HbA1c due to uremia and anemia, making the test less reliable.

Hemoglobin variants: Sickle cell disease, thalassemia, and other hemoglobinopathies interfere with some assay methods. Laboratories that use NGSP‑certified methods and have validated them for variant hemoglobins can still provide accurate results, but in such cases alternative markers like fructosamine or glycated albumin may be preferred.

Pregnancy: Physiological changes during pregnancy alter red cell turnover and plasma volume, so HbA1c may not accurately reflect glycemic control in the second and third trimesters. The ADA recommends using self‑monitored glucose levels and the glucose management indicator (derived from CGM) for gestational diabetes management.

Age and ethnicity: HbA1c levels tend to rise slowly with age even in normoglycemic individuals. Certain ethnic groups, including African American and Hispanic populations, have been shown to have slightly higher HbA1c values than white individuals for the same mean glucose. Clinicians should be aware of these nuances when setting treatment targets.

Medications and Supplements

Some medications can alter HbA1c independently of changes in mean glucose. For example, high‑dose salicylates (aspirin), certain antiretroviral drugs, and iron supplements may affect the test result. Patients should always inform their healthcare provider about all medications and supplements they are taking.

Glycemic Variability

A person with wide swings from hyperglycemia to hypoglycemia can have a misleadingly “normal” or “acceptable” HbA1c even though their daily glucose patterns are suboptimal. This phenomenon is known as the “HbA1c paradox.” For this reason, it is important to complement HbA1c with data from CGM or frequent fingerstick readings to assess time in range (TIR) and time below range.

Strategies to Lower HbA1c

Medical Nutrition Therapy

Dietary changes are the foundation of glycemic management. A registered dietitian can help patients adopt a pattern that emphasizes:

  • Carbohydrate consistency: Spreading carbohydrate intake evenly throughout the day reduces postprandial spikes.
  • High‑fiber foods: Whole grains, legumes, vegetables, and fruits with edible skins slow digestion and blunt glucose rises.
  • Reduced added sugars and refined grains: Substituting water for sugary drinks, limiting desserts, and choosing whole‑grain breads over white bread are effective steps.
  • Healthy fats: Monounsaturated and polyunsaturated fats (e.g., olive oil, nuts, avocados) improve insulin sensitivity.

For patients who require medical nutrition therapy, the ADA has published a comprehensive standards of care guide that provides evidence‑based recommendations.

Physical Activity

Regular exercise improves insulin sensitivity for up to 48 hours after a bout of activity. Both aerobic exercise (brisk walking, cycling, swimming) and resistance training (weightlifting, bodyweight exercises) have been shown to lower HbA1c by approximately 0.5–0.7% on average. The ADA recommends at least 150 minutes of moderate‑intensity aerobic activity per week, combined with two or three strength sessions. Importantly, patients should monitor blood glucose before and after exercise to prevent exercise‑induced hypoglycemia, especially if they take insulin or sulfonylureas.

Medication Optimization

When lifestyle modifications are insufficient, pharmacotherapy is indicated. The landscape of glucose‑lowering medications has expanded dramatically:

  • Metformin: First‑line oral agent for type 2 diabetes; reduces HbA1c by 1–1.5% through decreased hepatic glucose production and improved peripheral insulin sensitivity.
  • SGLT2 inhibitors: Lower HbA1c by 0.5–1% and also confer cardiovascular and renal benefits.
  • GLP‑1 receptor agonists: Promote insulin secretion and glucagon suppression; can lower HbA1c by 1–2% and support weight loss.
  • Insulin therapy: Essential for type 1 diabetes and often necessary in advanced type 2 diabetes. Basal‑bolus regimens offer the flexibility needed to achieve tight glycemic goals.

Any change in medication should be made under medical supervision, with regular follow‑up to assess HbA1c response and to adjust dosing.

Technology and Monitoring

The rise of continuous glucose monitoring (CGM) and automated insulin delivery (AID) systems has revolutionized diabetes management. CGM provides real‑time glucose trends and alerts for impending highs and lows, allowing patients to make proactive adjustments. Studies show that CGM use in both type 1 and type 2 diabetes is associated with significant reductions in HbA1c and improved time in range. The glucose management indicator (GMI), derived from CGM data, offers an analogue to HbA1c that can be updated every few weeks without a blood draw. The JDRF has been instrumental in advancing CGM technology and advocating for insurance coverage.

Limitations and Alternatives to HbA1c

When HbA1c May Be Misleading

As noted above, any condition that alters red blood cell lifespan or hemoglobin structure can produce an unreliable HbA1c. In addition, extreme hyperglycemia can cause falsely low HbA1c due to an interference known as “hemoglobin carbamylation” in renal failure. The test also averages out glycemic variability, so it cannot distinguish between stable control with moderate mean glucose versus erratic control that oscillates between extreme highs and lows.

Alternative Glycemic Markers

  • Fructosamine: Measures glycated serum proteins, reflecting control over the past two to three weeks. Useful when rapid feedback is needed.
  • Glycated albumin: Similar to fructosamine but less influenced by serum protein concentrations; good for monitoring short‑term changes.
  • 1,5‑anhydroglucitol: Reflects the frequency of postprandial hyperglycemia over the prior week or two. Not commonly used but can be helpful in certain clinical scenarios.
  • Time in range (TIR): From CGM data, TIR (70–180 mg/dL) is strongly correlated with HbA1c and provides a more actionable daily metric. Many clinicians now consider TIR a complementary standard to HbA1c.

Setting Realistic HbA1c Goals

The goal of diabetes management is not just a number; it is to prevent complications while preserving quality of life. A “good” HbA1c for one patient may be too aggressive for another. Shared decision‑making between patient and provider is essential. Factors to consider include:

  • Age: Older adults benefit from less stringent targets to minimize hypoglycemia.
  • Duration of diabetes: Shorter duration allows more room for tight control.
  • Established complications: Advanced microvascular or macrovascular complications may warrant relaxed targets.
  • Hypoglycemia unawareness: Patients who do not recognize low‑glucose symptoms need higher targets to avoid severe events.
  • Pregnancy plans: Preconception and pregnancy require very tight control (HbA1c <6.0–6.5%).

Regular review of HbA1c trends, combined with CGM data and patient feedback, allows for dynamic goal setting that adapts to changing circumstances.

Practical Tips for Patients

  • Keep a log: Track your daily glucose readings, meals, activity, and medications. Share this log with your provider.
  • Understand your trends: If your HbA1c is higher than expected, ask your provider to analyze your CGM report for patterns.
  • Avoid extreme lows: Severe hypoglycemia can be more dangerous than moderate hyperglycemia. Prioritize safety over perfection.
  • Engage a diabetes educator: Certified diabetes care and education specialists can help you make sustainable changes.
  • Use reliable resources: The CDC’s Diabetes Hub offers practical guidance on managing HbA1c.

Conclusion

HbA1c remains the gold‑standard biomarker for long‑term glycemic assessment in diabetes care. Its measurement provides a window into the cumulative effect of daily blood glucose fluctuations, allowing clinicians and patients to evaluate the effectiveness of lifestyle and pharmacologic interventions. Yet no single test tells the whole story. A comprehensive diabetes management plan must incorporate self‑monitoring, CGM data, dietary and exercise modifications, individualized medication regimens, and regular communication with a healthcare team. By understanding HbA1c—what it measures, how to interpret it, and what steps can improve it—patients can take control of their health and reduce the risk of devastating complications. Partner with your provider, set realistic targets, and remember that progress, not perfection, is the path to better outcomes.